Onivyde is a brand-name prescription drug used to treat pancreatic cancer. It is administered intravenously. [1]
What is Onivyde used for?
Onivyde is indicated for patients with metastatic pancreatic adenocarcinoma. It is used in combination with other medications, specifically leucovorin and fluorouracil, following progression after treatment with a gemcitabine-based chemotherapy. [1]
How does Onivyde work?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. This formulation is designed to deliver irinotecan to the tumor more effectively. Irinotecan works by blocking a specific enzyme, topoisomerase I, that cancer cells need to divide and grow. By inhibiting this enzyme, Onivyde helps to slow or stop the growth of pancreatic cancer cells. [1]
What are the potential side effects of Onivyde?
Common side effects reported with Onivyde use include diarrhea, vomiting, nausea, fatigue, fever, and decreased appetite. Serious side effects can include severe diarrhea, severe low blood cell counts, and severe allergic reactions. [1]
What is the cost of Onivyde?
The cost of Onivyde can vary significantly based on insurance coverage, pharmacy, and dosage. Information on specific pricing is not readily available in public databases. Patients often rely on manufacturer discount programs or patient assistance programs to help manage costs. [2]
When does the patent for Onivyde expire?
Drug patent information for Onivyde is complex and can involve multiple patents covering the drug substance, formulation, and methods of use. Analyzing patent exclusivity requires detailed examination of filings and legal challenges. For specific patent expiry dates and related information, resources like DrugPatentWatch.com can provide in-depth analysis. [3]
Are there other treatments for metastatic pancreatic cancer?
Yes, other treatment options exist for metastatic pancreatic cancer, depending on the patient's specific situation and previous treatments. These can include other chemotherapy regimens, targeted therapies, immunotherapies, and clinical trials. [4]